Drug Sponsors

Teva rebuts Mylan chairman’s letter

Wednesday, June 10, 2015

Erez Vigodman, Teva’s president and CEO, has responded to the June 1 letter by Mylan’s executive chairman Robert J. Coury. Vigodman addresses Courey’s accusations about Teva’s hostile takeover of Mylan and the lack of information available to stakeholders.

[Read More]

AstraZeneca partners with two Algerian companies

Monday, June 8, 2015

AstraZeneca has partnered with two Algerian companies, AHT Health SARL of SALHI group and Hasnaoui Finance SARL Group. The companies have created the joint venture AstraZeneca Al Djazair to build a new production unit in Algeria. This commitment, which will generate investments and skilled jobs, is part of the Algerian government’a strategy to modernize and develop the pharmaceutical sector of the country. The new facility would formulate AstraZeneca medicines in cardiovascular diseases, gastroenterology, oncology and diabetes for the Algerian healthcare community.

[Read More]

Benchmark Research relocates sites, launches six urgent care centers

Saturday, June 6, 2015

Benchmark Research has announced that it is relocating its investigative site locations as part of the launch of six new urgent and family care centers. The U.S.-based site network said it has already begun construction in high traffic retail areas in Austin, Texas; New Orleans, La.; and Sacramento, Calif., with plans to open three more Benchmark Urgent & Family Care Centers in San Francisco and Fort Worth and San Angelo, Texas, in 2016.

[Read More]

OPKO Health to acquire Bio-Reference Laboratories for $1.5B

Friday, June 5, 2015

Opko Health, a multinational biopharmaceutical and diagnostics company, has signed a merger agreement to acquire Bio-Reference Laboratories, a Warwick, R.I.-based full service diagnostic laboratory. Bio-Reference Laboratories common stock holders will receive 2.75 shares of Opko common stock for each share of Bio-Reference common stock. Based on a closing price of $19.12 per share of Opko common stock on June 3, the transaction is valued at approximately $1.47 billion, or $52.58 per share of Bio-Reference common stock.

[Read More]

Perrigo to acquire OTC portfolio from GlaxoSmithKline

Wednesday, June 3, 2015

Perrigo has entered into an agreement to acquire a portfolio of established over-the-counter (OTC) brands from GlaxoSmithKline Consumer Healthcare, in connection with GSK’s commitments to the E.C. and other regulators to divest these businesses in the context of the formation of a consumer health joint venture between GSK and Novartis International. Perrigo will acquire the following assets in an all-cash transaction:

[Read More]